A phase 1/1b study of CPI 006 as a single agent, in combination with ciforadenant and pembrolizumab in patients with advanced cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 May 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

29 Apr 2021 According to a Corvus Pharmaceuticals media release, the company plans to expand a cohort which is based on the identification of tumor types with biologic features best addressed by the unique mechanism of action of CPI-006.
12 Oct 2020 New trial record
05 Oct 2020 According to a Corvus Pharmaceuticals media release, the company has entered into a strategic collaboration with Angel Pharmaceuticals that will enable the development and commercialization of its pipeline of precisely targeted investigational medicines in China.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com